BioWorld

Oct. 6, 2008

Deciphera's B-Raf Inhibitor Program Lands Deal with Lilly

Privately held Deciphera Pharmaceuticals LLC signed its first big pharma deal, licensing rights to four preclinical B-Raf kinase inhibitors to Eli Lilly and Co. for the development of oncology drugs. (BioWorld Today) Read More

Another Case of PML: This Time Raptiva is Implicated

Repros Looks Inside to Close $15.5M Registered Direct Deal

NCI Studying Biomarker Use in Lung Cancer Treatment

Judge Says Amgen Entitled to Permanent Injunction in EPO Case

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026